Reinitiating ocrelizumab with a full 600 mg dose after extended treatment interruption: No increased risk of infusion-related reactions
{{output}}
Background: Infusion-related reactions (IRRs) are a common side-effect of ocrelizumab (OCR), with the highest risk occurring during treatment initiation. To minimize IRR risk, the first dose is split into two 300 mg infusions ove... ...
